Opioid use disorder

14,809views

Opioid use disorder

Watch later

Watch later

Sepsis
Infective endocarditis: Clinical
Endocarditis: Pathology review
Endocarditis
Fever of unknown origin: Clinical
Salmonella typhi (typhoid fever)
Plasmodium species (Malaria)
Schistosomes
Zinc deficiency and protein-energy malnutrition: Pathology review
Hypophosphatemia
Hyponatremia
Hyponatremia: Clinical
Hypertriglyceridemia
Hypertensive disorders of pregnancy: Clinical
Preeclampsia & eclampsia
Gestational hypertension
Gestational diabetes
Contraception: Clinical
Preterm labor
Erectile dysfunction
PDE5 inhibitors
Fallopian tube and uterus histology
Endometriosis
Chlamydia trachomatis
Neisseria gonorrhoeae
Treponema pallidum (Syphilis)
Congenital syphilis
Sexually transmitted infections: Clinical
HIV (AIDS)
Herpes simplex virus
Human papillomavirus
Endometrial hyperplasia
Endometrial cancer
Endometrial hyperplasia and cancer: Clinical
Ovarian cysts and tumors: Pathology review
Cervical cancer
Cervical cancer: Clinical
Cervical cancer: Pathology review
Ectopic pregnancy
Endometritis
Pelvic inflammatory disease
Ovarian germ cell tumors
Ovarian cysts, cancer, and other adnexal masses: Clinical
Sexual dysfunctions: Clinical
Anatomy clinical correlates: Wrist and hand
Placenta previa
Placental abruption
Vaginal versus cesarean delivery: Clinical
Antepartum hemorrhage: Clinical
Postpartum hemorrhage
Postpartum hemorrhage: Clinical
Urinary incontinence
Stages of labor
Shock
Shock: Clinical
Shock: Pathology review
Opioid agonists, mixed agonist-antagonists and partial agonists
Opioid use disorder
Opioid antagonists
Syncope: Clinical
Hypertension: Clinical
Hypertension
Hypertension: Pathology review
Local anesthetics
Ventricular arrhythmias: Pathology review
Supraventricular arrhythmias: Pathology review
Wolff-Parkinson-White syndrome
Ventricular fibrillation
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Atrial fibrillation
Atrial flutter
Ventricular tachycardia
Premature ventricular contraction
Heart failure
Heart failure: Pathology review
Heart failure: Clinical
Nephrotic syndromes: Pathology review
Nephritic and nephrotic syndromes: Clinical
Nephritic syndromes: Pathology review
Frank-Starling relationship
Aortic dissection
Aortic dissections and aneurysms: Pathology review
Aortic aneurysms and dissections: Clinical
Pericarditis and pericardial effusion
Atherosclerosis and arteriosclerosis: Pathology review
Angina pectoris
Leg ulcers: Clinical
Chronic venous insufficiency
Ischemic stroke
Stroke: Clinical
ECG cardiac hypertrophy and enlargement
Hypertrophic cardiomyopathy
Cardiomyopathies: Pathology review
Cardiomyopathies: Clinical
Dilated cardiomyopathy
Restrictive cardiomyopathy
Long QT syndrome and Torsade de pointes
Brugada syndrome
Action potentials in pacemaker cells
Asthma
Asthma: Clinical
Pneumonia
Pneumonia: Clinical
Pneumonia: Pathology review
Streptococcus pneumoniae
Pneumocystis jirovecii (Pneumocystis pneumonia)
Reading a chest X-ray
Mycobacterium tuberculosis (Tuberculosis)
Tuberculosis: Pathology review
Upper respiratory tract infection
General anesthetics
Lung cancer
Lung cancer: Clinical
Lung cancer and mesothelioma: Pathology review
Chronic obstructive pulmonary disease (COPD): Clinical
Sleep apnea
Apnea, hypoventilation and pulmonary hypertension: Pathology review
Sleep disorders: Clinical
Sleep
Narcolepsy (NORD)
Clinical Skills: BiPAP and CPAP
Restrictive lung diseases
Restrictive lung diseases: Pathology review
Diffuse parenchymal lung disease: Clinical
Idiopathic pulmonary fibrosis
Hypersensitivity pneumonitis
Sarcoidosis
Acetaminophen (Paracetamol)
Paracetamol toxicity
Non-steroidal anti-inflammatory drugs
Respiratory alkalosis
Metabolic and respiratory alkalosis: Clinical
Metabolic and respiratory acidosis: Clinical
Advanced cardiac life support (ACLS): Clinical
Respiratory acidosis
Pancoast tumor
Congenital cytomegalovirus (NORD)
Congenital TORCH infections: Pathology review
Alport syndrome
Pediatric ear, nose, and throat conditions: Clinical
Turner syndrome
Down syndrome (Trisomy 21)
Developmental milestones: Clinical
Neonatal sepsis
Auditory transduction and pathways
Muscular dystrophy
Cerebral palsy
Respiratory syncytial virus
Respiratory distress syndrome: Pathology review
Newborn management: Clinical
Neonatal respiratory distress syndrome
Appendicitis
Appendicitis: Clinical
Appendicitis: Pathology review
Meckel diverticulum
Neonatal jaundice: Clinical
Hirschsprung disease
Congenital gastrointestinal disorders: Pathology review
Pediatric allergies: Clinical
Pediatric constipation: Clinical
Pediatric vomiting: Clinical
Febrile seizure
Rotator cuff tear
Carpal tunnel syndrome
Achilles tendon rupture
Patellar tendon rupture
Anterior cruciate ligament injury
Spinal disc herniation
Sciatica
Degenerative disc disease
Compartment syndrome
Osteomyelitis
Bone tumors
Osteoporosis
Osteomalacia and rickets
Osteoarthritis
Rheumatoid arthritis
Gout
Psoriatic arthritis
Ankylosing spondylitis
Septic arthritis
Bursitis
Polymyositis
Dermatomyositis
Myasthenia gravis
Lambert-Eaton myasthenic syndrome
Sjogren syndrome
Systemic lupus erythematosus
Raynaud phenomenon
Platelet plug formation (primary hemostasis)
Coagulation (secondary hemostasis)
Role of Vitamin K in coagulation
Clot retraction and fibrinolysis
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Sensitivity and specificity
Positive and negative predictive value
Sickle cell disease (NORD)
Sickle cell disease: Clinical
Cystic fibrosis
Cystic fibrosis: Pathology review
Cystic fibrosis: Clinical
Phenylketonuria (NORD)
Non-corticosteroid immunosuppressants and immunotherapies
Glucocorticoids
Child abuse: Clinical
Abdominal hernias
Hernias: Clinical
Inguinal hernia
Femoral hernia
Volvulus
Varicocele
Nutcracker syndrome
Testicular tumors: Pathology review
Testicular torsion
Intestinal atresia
Tracheoesophageal fistula
Necrotizing enterocolitis
Diabetes mellitus
Diabetes mellitus: Clinical
Diabetes mellitus: Pathology review
Gestational diabetes
Hypoglycemics: Insulin secretagogues
Insulins
Diabetic nephropathy
Diabetic retinopathy
Diabetes insipidus
Insulin
Diabetes insipidus and SIADH: Pathology review
Pituitary gland histology
Anatomy of the thyroid and parathyroid glands
Thyroid and parathyroid gland histology
Pituitary tumors: Pathology review
Pituitary adenomas and pituitary hyperfunction: Clinical
Pituitary adenoma
Hyperprolactinemia
Prolactinoma
Cushing syndrome
Cushing syndrome: Clinical
Cushing syndrome and Cushing disease: Pathology review
Acromegaly
Gigantism
Hypopituitarism
Hypopituitarism: Clinical
Hypopituitarism: Pathology review
Hyperpituitarism
Pituitary apoplexy
Adrenal gland histology
Primary adrenal insufficiency
Adrenal insufficiency: Clinical
Adrenal insufficiency: Pathology review
Thyroid nodules and thyroid cancer: Clinical
Thyroid nodules and thyroid cancer: Pathology review
Thyroid cancer
Hashimoto thyroiditis
Thyroid storm
Thyroid hormones
Hypothyroidism and thyroiditis: Clinical
Hyperthyroidism
Hyperthyroidism: Pathology review
Hyperthyroidism: Clinical
Hyperthyroidism medications
Hypothyroidism
Hypothyroidism medications
Hypothyroidism: Pathology review
Toxic multinodular goiter
Graves disease
Cortisol
Renin-angiotensin-aldosterone system
Conn syndrome
Waterhouse-Friderichsen syndrome
Adrenal masses and tumors: Clinical
Adrenal masses: Pathology review
Skin cancer
Skin cancer: Pathology review
Skin cancer: Clinical
Sarcoptes scabiei (Scabies)
Anti-mite and louse medications
Psoriasis
Psoriatic arthritis
Eczematous rashes: Clinical
Atopic dermatitis
Contact dermatitis
Seborrhoeic dermatitis
Keratitis
Miscellaneous antifungal medications
Azoles

Transcript

Watch video only

Worldwide, opioids are the most common cause of drug-related deaths.
The number of individuals using opioids has drastically increased over time, with an uptick in heroin use, and an even bigger uptick in prescription opioid use, and a large number of people using both. Because of the potential for opioid use disorder and overdose, opioids are regulated substances in many countries.

As a class, opioids share one thing in common—they bind to opioid receptors in the brain, spinal cord, and gastrointestinal tract. Some are endogenous, meaning that they are produced naturally by the body, like endorphins, which are named for “endogenous morphine” due to their similar effects on the body. But others are exogenous, meaning that they come from outside the body, like heroin and morphine, which come from the opium poppy—a flowering plant that oozes a milky white liquid—while others like fentanyl are synthesized in the laboratory.

To understand how opioids work, let’s zoom in on a region of the spinal cord that has opioid receptors. Normally, in the absence of endorphins, nociceptive fibers carry pain signals from the body to the dorsal, or posterior, horn of the spinal cord.

Here they release neurotransmitters,

like glutamate, substance P and calcitonin gene-related peptide. These neurotransmitters cause pain signals to be transmitted to the brain via ascending pain pathways.

Now, let’s say someone goes to play a rigorous game of badminton. Exercise releases endorphins which activate the three major opioid receptors located on neurons, called the mu, kappa, and delta receptors.

As endorphins or other opioids bind to these receptors on the presynaptic terminals of nociceptive fibers, they inhibit the opening of calcium channels, preventing calcium influx, and thereby blocking the release of pain-causing neurotransmitters like glutamate, substance P and calcitonin gene-related peptide. At the same time, endorphins also bind to postsynaptic neurons, opening potassium channels here, leading to hyperpolarization and decreased excitability of the neuron. These effects together reduce the transmission of pain signals to the brain.

If we move up to the brain’s reward pathway, made up of midbrain regions like the ventral tegmental area, nucleus accumbens, and prefrontal cortex, we find another important effect of opioids.

Here, inhibitory neurons normally release gamma-aminobutyric acid, or GABA, at the presynaptic terminal, which in turn inhibits postsynaptic dopaminergic neurons, leading to decreased dopamine release.

But, when there are endorphins or opioids in the area, they bind to the opioid receptors on these inhibitory GABAergic neurons, causing a decrease in GABA release. With less GABA around, there is less inhibition of dopaminergic neurons, leading to a flood of dopamine in the brain’s reward center. This increased dopamine leads to a calming sensation and feelings of pleasure or euphoria, also known as an emotional “high”.

Now remember, the purpose of the reward pathway is to train the brain to repeat activities that cause dopamine-mediated pleasure, so when opioids stimulate this reward pathway, the brain learns to do that behavior again and again.

With exogenous opioids, there are multiple routes to get the drug to the brain.

One way is by ingesting it; that route is the slowest. A faster route would be inhalation because the drug is rapidly absorbed through the lungs; this route is not routinely used medically and is more commonly encountered with substance misuse.

The fastest route is direct injection of the substance into the blood. Typically, the faster the exogenous opioid reaches the brain, the stronger the relationship between the behavior and the reward.

Over time, people can develop tolerance to a drug. Tolerance means that with repeated use, their response to the drug decreases. As a result, even when taking the medication exactly as prescribed, a higher dose may be needed to achieve the same effect as before.

At a cellular level, there are two main reasons for why this happens.

One reason is that opioid receptors become less sensitive to stimulation by a drug, and the other reason is that the neurons may remove opioid receptors from the cell membrane in a process called down-regulation, leaving fewer receptors available for binding. In either scenario, tolerance leads to the need for higher and higher doses of a drug, and often that tolerance remains for a long time even after tapering off the drug.

Alright, so now let’s say that you’re at rest, there aren’t any drugs or anything else stimulating your reward pathway. In this situation, your brain keeps your heart rate, blood pressure, and wakefulness in a normal state, called homeostasis.

Now, let’s say you finally get a text with exam results that you’ve been waiting weeks for. All of a sudden you may feel sweaty and flushed, your heart rate may jump a bit. You’re now above your normal level of homeostasis, because something has changed, right? But it doesn’t stay that way for long, and after the text message, your brain brings things back down to this baseline.

With repeated drug use, a few things start to happen.
Let’s say you take a drug at a specific time and setting, like 3:00 P.M. in the bedroom, every day.

If it’s a depressant, it makes everything go lower: heart rate, blood pressure, and wakefulness.

Your brain, being the smart brain that it is, will pick up on this pattern.

So, the next time it’s 3:00 P.M. in the bedroom, your brain preemptively increases heart rate, blood pressure and wakefulness, since it knows that when you take the drug, everything’s going to decrease again.

Now, let’s say 3:00 P.M. in the bedroom rolls around, but there’s no drug…

In that situation, the brain still increases everything, but the changes aren’t countered with the effects of the drug, and so the person can feel awful;

these are called withdrawal symptoms. These symptoms can persist to the point where a person may need drugs just to feel normal, and if that’s the case, they are considered to be dependent on that drug.

Now, on the flipside, let’s say that you use the drug in an unfamiliar setting, like at 11:00 P.M. at a party. Well in that situation, your body’s not ready for the drug and there’s no physiologic “counterbalance” to help offset the effect of the drug.

When that happens, it can lead to overdose, even on a “normal” dose that the person’s taking, and that’s oftentimes what happens.

The symptoms of opioid withdrawal include dysphoric mood, myalgias, sweating and shivering, yawning, nausea, vomiting, and diarrhea, rhinorrhea, pupillary dilation, and insomnia.

These symptoms can feel really awful, and often prompt people to use opioids again. This is called negative reinforcement, since you’re removing the drug, which causes withdrawal symptoms which reinforces more drug use to avoid those symptoms.

Key Takeaways

An opioid use disorder is a medical condition that is characterized by the compulsive use of opioids in spite of adverse consequences from continued use and the development of a withdrawal syndrome when opioid use stops. Opioids include substances such as morphine, heroin, codeine, oxycodone, hydrocodone, etc. The necessary descriptive characteristics of the medical diagnosis are preoccupation with a desire to obtain and take the drug and persistent drug-seeking behaviour. 

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine" McGraw Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "Pharmacological therapies for management of opium withdrawal" Cochrane Database of Systematic Reviews (2018)
  5. "An examination of psychiatric comorbidities as a function of gender and substance type within an inpatient substance use treatment program" Drug and Alcohol Dependence (2011)
  6. "Cellular basis of memory for addiction" Dialogues in Clinical Neuroscience (2013)